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Osteoarthritis and the metabolic syndrome: more evidence that the etiology of OA
is different in men and womenProjections by the Centers for Disease Control (CDC) suggest
that if current trends continue, by 2030, 20% of the US population
will be over age 65, and 86% or the population will be overweight
or obese1,2. As our population ages and becomes more obese, prev-
alence is increasing for diseases related to aging and obesity, such
as osteoarthritis (OA) and the metabolic syndromeda cluster of
cardio-metabolic risks secondary to impaired insulin action
including hypertension, increased abdominal girth, hypertriglycer-
idemia, low high density lipoprotein (HDL-cholesterol), and
elevated fasting glucose.
While both have aging and excess adiposity as important risk
factors, OA and the metabolic syndrome have only recently been
associated with one another. In the US National Health and Nutri-
tion Examination Survey (NHANES), wave III (1988–1994), with
data from over 7,000 adults, each component of the metabolic
syndromewas more prevalent in persons with OA3. In the Japanese
Research on Osteoarthritis Against Disability (ROAD), the odds of
OA increased with the presence of each additional component of
the metabolic syndrome4. Similarly, In the Michigan Bone Health
and Metabolism Study, in obese women, the presence of two or
more cardio-metabolic risk factors was associated with more
reports of persistent knee pain over the previous 3 years5.
While obesity is a well-recognized risk factor for OA in weight-
bearing knee joints6,7, the association of OA with the metabolic
syndrome is not completely explained by an obesity-induced
increased biomechanical load. Overweight and obese persons also
have an increased risk for OA in hands, which are not weight-
bearing, implicating systemic factors in the obesity-OA connec-
tion8,9. Likely, the systemic connection between OA and the
metabolic syndrome revolves around altered metabolism and
inﬂammation. The pathogenesis of OA and themetabolic syndrome
each involve abnormalities in common metabolic intermediates
including glucose, hormones, several growth factors, transcription
factors, nitric oxide and reactive oxygen species10. Further, over
the last several decades, both OA and the metabolic syndrome
have been increasingly recognized as low-grade inﬂammatory
conditions with elevations in systemic inﬂammatory markers
such as hsCRP11,12. For both entities, there are clear pathogenic roles
for inﬂammatory mediators such as IL1b and TNFa10. Additionally,
leptin, a pro-inﬂammatory hormone produced by macrophages in
adipose tissue and a key mediator of the metabolic dysregulation
associated with obesity, has been linked to OA pathogenesis10. Lep-
tin is best known for regulating energy intake as an appetite
suppressant, but also plays a role in osteoclast and chondrocyte
proliferation and collagen synthesis10.1063-4584/$ – see front matter  2012 Osteoarthritis Research Society International. Pu
doi:10.1016/j.joca.2012.04.007In work published in this issue, Karvonen-Gutierrez, Sowers,
and Heeringa have contributed new insights to the mechanisms
linking OA and the metabolic syndrome. They observe that rela-
tions between OA and cardio-metabolic risk factors, including lep-
tin, are present for both genders and in both obese and non-obese
individuals. However, their work demonstrates that these relations
differ between men and women in both magnitude, and the
speciﬁc molecules and pathways involved. These authors used
data from NHANES III (1988–1994) participants 60 years of age
and older who had both fasting blood samples and knee radio-
graphs. Knee radiographs were non-weight bearing so that, while
not accounting for joint space narrowing or cartilage degradation,
the OA deﬁnition primarily reﬂected the presence of osteophytes.
Of the 1,066 participants included in this analysis, 34% had OA,
deﬁned as a Kellgren–Lawrence (KL) grade  2. Not surprisingly,
persons with OA had a higher BMI (40% were obese). Similar to
Puenpatom and Victor3, glucose, LDL-cholesterol, triglycerides,
and blood pressure were signiﬁcantly higher and HDL-cholesterol
was signiﬁcantly lower in persons with OA than those without. In
addition to the earlier report, even after adjustments for covariates,
this investigation revealed strong relations for OAwith homeostatis
model assessment-insulin resistance (HOMA-IR), a surrogate for
insulin resistance, and leptin.
Most notably, the authors report relations for these cardio-
metabolic risk factors and knee OA that were unique for each
gender and obesity status. In non-obese men, body mass index
(BMI) and HOMA-IR were the risk factors most strongly related to
knee OA. In obese men, BMI was not related to knee OA, but
HOMA-IR was again the risk factor most strongly related. For
both non-obese and obese women, BMI continued to be a strong
predictor of knee OA, but in contrast to other strata, HOMA-IR
was inversely related to knee OA in obese women. Leptin relations
were particularly interesting. For women, there were positive asso-
ciations such that for obese women an increase of 5 fg/L of leptin
contributed a 1.28 increased odds of radiographic knee OA. In
contrast, for both non-obese and obese men, leptin levels were
inversely related to the presence of radiographic OA.
These ﬁndings highlight that independent of the effects of
obesity, altered metabolism is related to knee OA, but that these
relations differ for men and women. While insulin resistance is
associated with an increased odds of knee OA in men, increased
leptin is associated with increased odds in women, perhaps reﬂect-
ing the previously observed gender differences in relations
between these risk factors and fat deposition. Typically, insulin
resistance is more strongly related to visceral adiposity, which is
particularly prominent as a cardiovascular risk factor in men, andblished by Elsevier Ltd. All rights reserved.
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tends to be a predominant fat depot for women13.
Given the increased prevalence of OA in women, gender differ-
ences in associated factors and potential mediators are not too
surprising. Gender differences have been noted for OA at epidemio-
logic, radiographic, circulating biomarker, hormonal, and cellular
levels. A gender dimorphism exists for the impact of OA on pain
and quality of life such that women report higher levels of pain
and greater reductions in quality of life than men14,15. A review of
magnetic resonance imaging (MRI) comparisons of men and women
highlights variability in ﬁndings but concludes that women appear
to have lower knee cartilage volume than men16. Despite similar
KL grades, as compared to men, women exhibit higher levels of
the bone resorption biomarker, serum C-terminal telopeptide of
collage type I (CTX-I), and the cartilage degradation biomarker, urine
C-terminal telopeptide of collage type II (CTX-II)17. In contrast, men
exhibit higher levels of serum hyaluronan (HA), an indicator of
synovial inﬂammation suggesting gender-speciﬁc pathogenic mech-
anisms16. Gender differences in OA have been attributed to differ-
ences in sex hormones, as lower levels of estradiol and its catabolic
metabolite, urinary 2-hydroxyestrone are associated with the devel-
opment of knee OA18. Interestingly, both estrogen and testosterone
inﬂuence chondrocyte progenitor potential but through unique
gene expression and regulatory pathways16.
Thus, a gender dimorphism clearly exists for OA atmultiple levels
and as reinforced in the work of these authors. Such differences
suggest that OA pathogenesis might proceed via unique gender-
speciﬁc pathways based on underlying hormonal and anatomic
differences. As we seek to better understand the metabolic and
inﬂammatory contributions to OA, it is imperative that we continue
to carefully evaluate for potential differences by gender.
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